Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00440-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_infocusoncology_esmo24&_hsenc=p2ANqtz-80FqBC_qmrmrlNi7OM3pBo0cOeCsJh831MY25gb9V9L5qMYDCNK7tNpPbjSJ50yjDozjm9oD1LxLNw_4HqwsxlI67mMQ&_hsmi=325179166&utm_content=325179166&utm_source=hs_email